SU5214
98%
- Product Code: 102660
CAS:
186611-04-1
| Molecular Weight: | 251.285 g./mol | Molecular Formula: | C₁₆H₁₃NO₂ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD01595259 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
SU5214 is primarily utilized in research settings as a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). It plays a crucial role in studying angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting VEGFR-2, SU5214 helps researchers understand the mechanisms of tumor growth and metastasis, as angiogenesis is a critical factor in cancer progression. Additionally, it is used in preclinical studies to evaluate the efficacy of anti-angiogenic therapies, providing insights into potential treatments for various cancers and other diseases characterized by abnormal blood vessel formation. Its application extends to exploring the role of VEGFR-2 in other pathological conditions, such as rheumatoid arthritis and diabetic retinopathy, where angiogenesis is also a contributing factor.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White Solid |
| Purity (%) | 97.5-100 |
| Nmr | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿1,940.00 |
+
-
|
| 0.005 | 10-20 days | ฿8,730.00 |
+
-
|
SU5214
SU5214 is primarily utilized in research settings as a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). It plays a crucial role in studying angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting VEGFR-2, SU5214 helps researchers understand the mechanisms of tumor growth and metastasis, as angiogenesis is a critical factor in cancer progression. Additionally, it is used in preclinical studies to evaluate the efficacy of anti-angiogenic therapies, providing insights into potential treatments for various cancers and other diseases characterized by abnormal blood vessel formation. Its application extends to exploring the role of VEGFR-2 in other pathological conditions, such as rheumatoid arthritis and diabetic retinopathy, where angiogenesis is also a contributing factor.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :